- Email: [email protected]
Autonomy Run Amok: Refashioning End-of-Life Decision Making (304)
454
Schedule with Abstracts
erature in 2008 relevant to hospice and palliative care clinical practice. 2. The learner will become familiar with the PCFACS publication from AAHPM and the potential role it has in his or her own clinical practice. As clinicians on the front line of practice, we must stay up-to-date with the evidence in order to provide competent best care to patients. Yet, the volume of pertinent information for palliative care providers working in hospitals, long-term care facilities, community practices, and hospice programs is unwieldy, exhausting to manage, and rapidly expanding. PC-FACS (Palliative Care—Fast Article Critical Summaries) is an AAHPM publication designed to help busy clinicians stay on top of current best evidence relevant to contemporary palliative medicine practice but which, due to the cross-disciplinary nature of palliative care, may not appear in palliative care–specific publications. High-quality articles are selected through careful review of over 60 medical and scientific journals published outside the traditional palliative care literature. In a convenient, electronic, biweekly, digest format, concise summaries of the most relevant, newsworthy articles are presented with brief commentary tailored to the evidence needs of the practicing palliative care and hospice clinician. During 2008, PC-FACS reviewed over 100 pertinent articles which might have escaped the notice of many evidence-conscious clinicians. This session will spotlight the PC-FACS “best evidence of 2008” and provide insight into emerging clinical research and its incorporation into the current body of palliative care evidence. Domains All Domains
New Drugs and Drug News: The 411 and Implications for Palliative Care (303) Mary Lynn McPherson, PharmD BCPS CDE, University of Maryland, Annapolis, MD (McPherson has disclosed the following relevant financial relationships: consultant for Alpharma.) Objectives 1. List new drugs approved by the FDA in 2008. For each drug, the participant will be able to describe the approved indication, unapproved uses of the medication, common adverse effects, and drug interactions. 2. For each new medication approved in 2008, describe the burden-to-benefit ratio and the
Vol. 37 No.3 March 2009
role of the medication in caring for patients with advanced illness. 3. Analyze important drug alerts released by the FDA (Public Health Advisories) and their relevance to drug therapies commonly used in hospice and palliative care patients. Up to 100 new drugs are approved every year by the Food and Drug Administration (FDA). Some of these are new molecular entities, while others are new formulations, new indications, generic drug approvals, or labeling revisions. Even if a drug is a “new” molecular entity, it may not be “improved” over molecular entities already commercially available. In caring for patients with advanced illnesses, practitioners must make prudent drug-therapy choices. Part of this decisionmaking process is a careful assessment of the burden-to-benefit ratio, including the financial burden of using each medication. This concurrent session is a follow-up to last year’s very popular update on new drugs. For relevant drugs approved in 2008, participants will learn about the FDA-approved indication for using the medication, unapproved uses of the medication (particularly as it applies to palliative care patients), if it is a controlled substance and the schedule (if appropriate), adverse effects, major drug interactions, dosing, and financial implications of drug procurement and monitoring, if relevant. Participants will learn what “NDA Chemical Type” (eg, new molecular entity, formulation, manufacturer, indication, or OTC switch) and “Review Classification” (ie, priority or standard review, orphan drug status) were assigned by the FDA. If available, participants will also learn the “new drug comparison rating” (1-5, 5 highest in terms of drug importance). Most importantly, the participant will learn about the role of the new agent in caring for patients with advanced illnesses and how the medication compares with medications already available. Public-health advisories related to drug therapy will also be discussed, as will their impact on caring for palliative care patients. Inappropriate use of medications in hospice or palliative care patients may result in suboptimal symptom management. This is a session that every healthcare professional needs to attend. Domain Physical Aspects of Care
Schedule with Abstracts
erature in 2008 relevant to hospice and palliative care clinical practice. 2. The learner will become familiar with the PCFACS publication from AAHPM and the potential role it has in his or her own clinical practice. As clinicians on the front line of practice, we must stay up-to-date with the evidence in order to provide competent best care to patients. Yet, the volume of pertinent information for palliative care providers working in hospitals, long-term care facilities, community practices, and hospice programs is unwieldy, exhausting to manage, and rapidly expanding. PC-FACS (Palliative Care—Fast Article Critical Summaries) is an AAHPM publication designed to help busy clinicians stay on top of current best evidence relevant to contemporary palliative medicine practice but which, due to the cross-disciplinary nature of palliative care, may not appear in palliative care–specific publications. High-quality articles are selected through careful review of over 60 medical and scientific journals published outside the traditional palliative care literature. In a convenient, electronic, biweekly, digest format, concise summaries of the most relevant, newsworthy articles are presented with brief commentary tailored to the evidence needs of the practicing palliative care and hospice clinician. During 2008, PC-FACS reviewed over 100 pertinent articles which might have escaped the notice of many evidence-conscious clinicians. This session will spotlight the PC-FACS “best evidence of 2008” and provide insight into emerging clinical research and its incorporation into the current body of palliative care evidence. Domains All Domains
New Drugs and Drug News: The 411 and Implications for Palliative Care (303) Mary Lynn McPherson, PharmD BCPS CDE, University of Maryland, Annapolis, MD (McPherson has disclosed the following relevant financial relationships: consultant for Alpharma.) Objectives 1. List new drugs approved by the FDA in 2008. For each drug, the participant will be able to describe the approved indication, unapproved uses of the medication, common adverse effects, and drug interactions. 2. For each new medication approved in 2008, describe the burden-to-benefit ratio and the
Vol. 37 No.3 March 2009
role of the medication in caring for patients with advanced illness. 3. Analyze important drug alerts released by the FDA (Public Health Advisories) and their relevance to drug therapies commonly used in hospice and palliative care patients. Up to 100 new drugs are approved every year by the Food and Drug Administration (FDA). Some of these are new molecular entities, while others are new formulations, new indications, generic drug approvals, or labeling revisions. Even if a drug is a “new” molecular entity, it may not be “improved” over molecular entities already commercially available. In caring for patients with advanced illnesses, practitioners must make prudent drug-therapy choices. Part of this decisionmaking process is a careful assessment of the burden-to-benefit ratio, including the financial burden of using each medication. This concurrent session is a follow-up to last year’s very popular update on new drugs. For relevant drugs approved in 2008, participants will learn about the FDA-approved indication for using the medication, unapproved uses of the medication (particularly as it applies to palliative care patients), if it is a controlled substance and the schedule (if appropriate), adverse effects, major drug interactions, dosing, and financial implications of drug procurement and monitoring, if relevant. Participants will learn what “NDA Chemical Type” (eg, new molecular entity, formulation, manufacturer, indication, or OTC switch) and “Review Classification” (ie, priority or standard review, orphan drug status) were assigned by the FDA. If available, participants will also learn the “new drug comparison rating” (1-5, 5 highest in terms of drug importance). Most importantly, the participant will learn about the role of the new agent in caring for patients with advanced illnesses and how the medication compares with medications already available. Public-health advisories related to drug therapy will also be discussed, as will their impact on caring for palliative care patients. Inappropriate use of medications in hospice or palliative care patients may result in suboptimal symptom management. This is a session that every healthcare professional needs to attend. Domain Physical Aspects of Care